Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.4.2.8 (
hypoxanthine-guanine phosphoribosyltransferase
)
2,527
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Prostate cancer is the most commonly diagnosed malignancy in male populations in the Western world. The
KLK15
gene, the newest member of the kallikrein family, is expressed in the prostate gland. The purpose of this study is the expression analysis and the clinical evaluation of the
KLK15
mRNA spliced variants in prostate cancer (CaP) and benign prostatic hyperplasia (BPH) patients. Total RNA was isolated from 104 CaP and BPH tissue specimens. After testing the quality of the RNA, cDNA was produced by reverse transcription, and PCR was performed for the amplification of the
KLK15
mRNA transcripts. GAPDH and
HPRT
genes were used as endogenous controls Our data revealed that mRNA spliced variants of
KLK15
were differentially expressed in prostate tissue specimens. Analysis of data showed a statistically significant (P < 0.001) increase in the frequency of overexpression of
KLK15
transcripts encoding for both the active isoform and for the isoform 3 in CaP compared to BPH samples. Furthermore,
KLK15
transcripts were found to be highly expressed in more aggressive tumors (P = 0.017). These results suggest that
KLK15
expression analysis could be employed as a valuable tool for the discrimination between BPH and CaP tissue specimens and as an unfavorable prognostic marker for prostate cancer.
...
PMID:Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia. 2006 63